Theranos Inc.'s main retail partner threatened to terminate its
relationship with the blood-testing company unless it quickly fixes
the problems found by federal inspectors at a laboratory in
California, people familiar with the matter said.
The warning from drugstore chain Walgreens was issued in a
letter to Theranos late last month and gives closely held Theranos,
based in Palo Alto, Calif., a 30-day deadline that expires near the
end of February to resolve major infractions that violate the U.S.
law governing clinical labs, these people said.
The 40 Theranos "wellness centers" at Walgreens stores in
Arizona are the primary source of revenue for the blood-testing
company and its conduit to consumers. Theranos and Walgreens, a
unit of Walgreens Boots Alliance Inc., have been in negotiations
about the future of their partnership since shortly after an
October article in The Wall Street Journal that raised questions
about the blood-testing company's technology.
The two companies originally planned to offer blood tests
nationwide. Walgreens has more than 8,000 stores. In the past few
months, though, the drugstore chain has frozen the plans to expand,
stopped sending patients' blood samples to the California lab and
been assessing the overall viability of its relationship with
Theranos.
Brooke Buchanan, a Theranos spokeswoman, declined to comment for
this article, as did Walgreens spokesman Michael Polzin.
Talks between the two companies are continuing, said people
familiar with the matter. Theranos has previously said the
inspection findings don't "reflect the current state of the
lab."
The company has said it "addressed many of the observations
during the survey" and is "actively continuing to take corrective
action."
"Should the Theranos-Walgreens partnership dissolve, that would
effectively mean they'd cease to be a competitor to other labs,"
said William Quirk, a laboratory-industry analyst at Piper Jaffray
Cos.
Without Walgreens, Theranos would need to forge a new retail
partnership to regain access to consumers, Mr. Quirk added.
Otherwise, Theranos would have to battle other lab companies,
including giants Laboratory Corp. of America Holdings and Quest
Diagnostics Inc., for blood-testing business through doctors'
offices.
Theranos faces a separate deadline of Friday to submit to the
Centers for Medicare and Medicaid Services a plan to fix the
problems uncovered during an inspection completed last fall at the
company's lab in Newark, Calif.
The infractions found in one area "pose immediate jeopardy to
patient health and safety," the agency said.
The deadline has been extended once, and additional extensions
are possible. The federal agency could begin imposing sanctions if
Theranos remains out of compliance as of late March, according to a
person familiar with the matter.
Walgreens issued its warning letter to Theranos after
discussions on Jan. 28 with the blood-testing company's founder and
chief executive, Elizabeth Holmes.
In a telephone call that day, Walgreens officials told Ms.
Holmes the drugstore chain would continue working with Theranos if
she agreed to suspend all blood testing and certain other
operations until the problems identified by federal inspectors were
resolved, according to the people familiar with the matter.
Ms. Holmes declined, the people said. She also suggested
Walgreens might be in breach of its contract with Theranos for
suggesting the suspension.
Ms. Holmes, 32 years old, started Theranos in 2003 and steered
it to a valuation of about $9 billion in a funding round in
2014.
The discussions with Ms. Holmes occurred during a regularly
scheduled Walgreens board meeting at the Park Hyatt hotel in New
York City.
Walgreens executives shuffled between the phone call with Ms.
Holmes, briefing directors on the matter and preparing a news
release about the decision to stop for now sending samples to
Theranos's lab in California, according to the people familiar with
the situation. The drugstore chain also announced the temporary
closure of the wellness center in its Palo Alto store.
The contract with Theranos hasn't generated revenue for
Walgreens, and the drugstore chain lent Theranos at least $50
million in the form of debt that is convertible to equity, people
familiar with the matter said.
Separately, Theranos and the Cleveland Clinic haven't reached an
agreement on the terms of a study they would jointly run to compare
Theranos's technology with more-traditional blood-testing
techniques, according to a person familiar with the
relationship.
The hospital system's chief executive, Toby Cosgrove, said in
October that Theranos had agreed to run such a study with the
Cleveland Clinic. The Cleveland Clinic also has a "long-term
strategic alliance" to use Theranos's technology.
In January, three Cleveland Clinic scientists visited Theranos's
headquarters, where they were shown the company's proprietary
devices but not told how the devices work, this person said. Mr.
Cosgrove declined to comment.
Write to Christopher Weaver at christopher.weaver@wsj.com,
Michael Siconolfi at michael.siconolfi@wsj.com and John Carreyrou
at john.carreyrou@wsj.com
(END) Dow Jones Newswires
February 10, 2016 22:05 ET (03:05 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Oct 2023 to Oct 2024